LOS ANGELES CAPITAL MANAGEMENT LLC

Position in FULC — Fulcrum Therapeutics, Inc.

CIK 1177206 LOS ANGELES, CA

Position in FULC

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$1,079

-$1,183 QoQ

Shares Held

295

0.0% QoQ

Ownership

0.000%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#142

of 154 holders

Holding Since

Mar 2020

9 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,562,834 across 167 Biotechnology names. FULC ranks #165 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	729,635	$219,642,024
2	HALO	Halozyme Therapeutics, Inc.	1,938,035	$151,689,999
3	CAI	Caris Life Sciences, Inc.	3,958,531	$70,541,022
4	INCY	Incyte Corp	578,986	$65,633,852
5	VRTX	Vertex Pharmaceuticals Inc / Ma	130,802	$64,973,277
6	EXEL	Exelixis, Inc.	1,159,457	$63,086,055
7	REGN	Regeneron Pharmaceuticals, Inc.	98,585	$61,471,690
8	RPRX	Royalty Pharma plc	877,674	$49,211,181

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,079	295	0.0%	Shares	Sole	2026-08-13
2026-03-31	$2,262	295	-67.8%	Shares	Sole	2026-05-08
2025-12-31	$10,348	915	-93.2%	Shares	Sole	2026-02-11
2025-06-30	$92,639	13,465	-36.0%	Shares	Sole	2025-08-07
2024-06-30	$130,435	21,038	+1.4%	Shares	Sole	2024-08-05
2020-12-31	$243,064	20,757	-34.0%	Shares	Sole	2021-03-10
2020-09-30	$249,557	31,470	+102.0%	Shares	Sole	2020-11-02
2020-06-30	$284,939	15,579	+46.6%	Shares	Sole	2020-08-05
2020-03-31	$126,910	10,629	—	Shares	Sole	2020-05-04
No filing history on record for this holder in this stock.